Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.56 |
| ▸ | MGLL | Q99685 | 6/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21518529 | 0.89 | PTGS1 (0.48) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL27420589 | 0.84 | PTGS1 (0.62) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL16453429 | 0.82 | PTGS1 (0.59) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL19708800 | 0.82 | PTGS1 (0.59) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL21320461 | 0.80 | PTGS1 (0.56) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6832676 | 0.79 | PTGS1 (0.46) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL27431238 | 0.79 | PTGS1 (0.55) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL14969087 | 0.78 | PTGS1 (0.50) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL17029469 | 0.77 | PTGS1 (0.52) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL17721377 | 0.76 | PTGS1 (0.58) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522916-B2 | A1 adenosine receptor antagonists | WILSON CONSTANCE NEELY (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140031375-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | WILSON CONSTANCE NEELY (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2222676-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009086077-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1636229-A4 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-7247639-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1636229-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005009343-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA3, ADORA2A | PTGS1 2818/4885PTGS2 4380/4885MGLL 3223/4885 |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | HRH3, HRH1, HRH2 | PTGS1 276/4885PTGS2 408/4885MGLL 4141/4885 |
| US-20140031375-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | PTGS1 505/4885PTGS2 1366/4885MGLL 3474/4885 |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | PTGS1 930/4885PTGS2 2105/4885MGLL 3473/4885 |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA3, ADORA2A | PTGS1 1191/4885PTGS2 2255/4885MGLL 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.